Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 5:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 1,505 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Positron emission tomography-computed tomography (PET/CT) Clear all
Recruiting Phase 1 Interventional

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

NCT03017820
View directory record Official record
Conditions
B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm, Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mycosis Fungoides, Recurrent Plasma Cell Myeloma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Acute Myeloid Leukemia, Refractory Anaplastic Large Cell Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Plasma Cell Myeloma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Positron Emission Tomography, Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter, Single Photon Emission Computed Tomography, Cemiplimab, Ruxolitinib, Nivolumab, Multigated Acquisition Scan, Echocardiography Test, Bone Marrow Aspiration
Procedure · Drug · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2032
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 14, 2026, 5:35 AM EDT
Recruiting Phase 1 Interventional

Evaluating the Use of Dual Imaging Techniques for Detection of Disease in Patients With Head and Neck Cancer

NCT05945875
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions
Panitumumab-IRDye800, Indium In 111 Panitumumab, Single Photon Emission Computed Tomography, Computed Tomography, Resection, Fluorescence Imaging
Drug · Other · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
19 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 14, 2026, 5:35 AM EDT
Completed Not applicable Interventional

Parametric PET of Genitourinary Cancer

NCT04020978
View directory record Official record
Conditions
Genitourinary Cancer
Interventions
Parametric PET/CT
Diagnostic Test
Lead sponsor
University of California, Davis
Other
Eligibility
21 Years to 100 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 14, 2026, 5:35 AM EDT
Completed Phase 1Phase 2 Interventional Results available

PET/CT Quantitative Assessment of Myocardial Blood Flow Changes in Oncologic Patients Receiving Checkpoint Inhibitor Therapy

NCT04538950
View directory record Official record
Conditions
Cancer
Interventions
PET/CT, radioactive drug (tracer)
Diagnostic Test · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 14, 2026, 5:35 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Nicotinic Hepatic Metabolism on Neuroreceptor Substrates of Nicotine Addiction

NCT03442413
View directory record Official record
Conditions
Smoking, Tobacco
Interventions
2-[18F]-FA PET/CT, I.V. Nicotine
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 14, 2026, 5:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Radiation Dosimetry, Metabolism, Pharmacokinetics, Safety and Tolerability and PET Imaging With BAY94-9392 in Healthy Volunteers and Patients With Cancer or Inflammation

NCT01103310
View directory record Official record
Conditions
Diagnostic Imaging, Neoplasms
Interventions
BAY94-9392
Drug
Lead sponsor
Lantheus Biosciences Ltd.
Industry
Eligibility
35 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2014 · Synced Oct 14, 2026, 5:35 AM EDT
Recruiting Phase 3 Interventional

Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis

NCT07578116
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma, Oligometastatic Breast Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Breast Conservation Treatment, Computed Tomography, Cyclin-Dependent Kinase 4 Inhibitor, Cyclin-Dependent Kinase 6 Inhibitor, Echocardiography Test, HER2-targeted Therapy, Hormone Therapy, Magnetic Resonance Imaging, Mammography, Pertuzumab, Positron Emission Tomography, Radiation Boost, Radiation Therapy, Stereotactic Body Radiation Therapy, Stereotactic Radiosurgery, Taxane Compound, Total Mastectomy, Trastuzumab, Trastuzumab Deruxtecan, Trastuzumab Emtansine, Ultrasound Imaging
Procedure · Drug · Biological + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
562 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2033
U.S. locations
59
States / cities
Jonesboro, Arkansas • Derby, Connecticut • Fairfield, Connecticut + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 14, 2026, 5:35 AM EDT
Completed Phase 2Phase 3 Interventional Results available

68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer

NCT02624518
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
68Ga-RM2, Magnetic Resonance Imaging, Positron Emission Tomography
Drug · Procedure
Lead sponsor
Andrei Iagaru
Other
Eligibility
18 Years and older · Male only
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 14, 2026, 5:35 AM EDT
Recruiting Phase 2 Interventional

Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial

NCT07605416
View directory record Official record
Conditions
Plasma Cell Leukemia
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Carfilzomib, Computed Tomography, Daratumumab and Recombinant Human Hyaluronidase, Dexamethasone, Fludeoxyglucose F-18, Lenalidomide, Magnetic Resonance Imaging, Melphalan, Plerixafor, Positron Emission Tomography, Recombinant Granulocyte Colony-Stimulating Factor, Stem Cell Isolation, Teclistamab, Transthoracic Echocardiography Test
Procedure · Drug · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
10
States / cities
New Haven, Connecticut • North Haven, Connecticut • Baton Rouge, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 14, 2026, 5:35 AM EDT
Terminated Not applicable Interventional Results available

Gated and Non-Gated Dynamic PET/CT Imaging

NCT04283552
View directory record Official record
Conditions
Dynamic PET/CT Imaging
Interventions
Dynamic PET/CT Imaging
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Oct 14, 2026, 5:35 AM EDT
Recruiting Not applicable Interventional

Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate CancEr

NCT05948657
View directory record Official record
Conditions
Prostate Cancer
Interventions
PSMA-PET CT
Diagnostic Test
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 14, 2026, 5:35 AM EDT
Terminated Phase 1 Interventional

Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer

NCT01494012
View directory record Official record
Conditions
Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Malignant Tumor of Peritoneum, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor
Interventions
stereotactic body radiation therapy, positron emission tomography, computed tomography, questionnaire administration, fludeoxyglucose F 18
Radiation · Procedure · Other + 1 more
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 14, 2026, 5:35 AM EDT
No Longer Available No phase listed Expanded access

Study of the Use of [18F]-DOPA in Hyperinsulinemic Hypoglycemia

NCT02533219
View directory record Official record
Conditions
Hyperinsulinemic Hypoglycemia, Persistent, Congenital Hyperinsulinism, Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI)
Interventions
18 F-DOPA
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 64 Years
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 7, 2020 · Synced Oct 14, 2026, 5:35 AM EDT
Completed Early Phase 1 Interventional

FDG PET Imaging in Diagnosing Patients With Glioblastoma

NCT02885272
View directory record Official record
Conditions
Brain Glioblastoma
Interventions
Computed Tomography, Fludeoxyglucose F-18, Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
19 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 14, 2026, 5:35 AM EDT
Completed Not applicable Interventional Results available

89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Glioblastoma Multiforme

NCT02410577
View directory record Official record
Conditions
Glioblastoma
Interventions
89Zr-J591, PET/CT Scan, MRI, Blood draw
Drug · Device · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
26 Years to 79 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Oct 14, 2026, 5:35 AM EDT
Completed No phase listed Observational

Non-Invasive Cerenkov Luminescence Imaging of Lymphoma, Leukemia and Metastatic Lymph Nodes

NCT01664936
View directory record Official record
Conditions
Head and Neck Cancers
Interventions
Cerenkov emissions from the PET tracer 18F-FDG and the radiotherapeutic 131I
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 14, 2026, 5:35 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Control of Renal Oxygen Consumption, Mitochondrial Dysfunction, and Insulin Resistance

NCT04074668
View directory record Official record
Conditions
Diabetic Kidney Disease, Type 1 Diabetes, Diabetes, Diabetes Mellitus, Diabetes Complications, Diabetic Nephropathies, Type1diabetes, Diabetes, Autoimmune, Autoimmune Diabetes, Juvenile Diabetes, Type 1 Diabetes Mellitus
Interventions
Aminohippurate Sodium Inj 20%, Iohexol Inj 300 milligrams/milliliter (mg/ml), PET/CT Scan, Renal Biopsy
Drug · Radiation · Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 30 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 14, 2026, 5:35 AM EDT
Terminated Phase 2 Interventional Results available

ZD4054 With Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) for Prostate Cancer

NCT01119118
View directory record Official record
Conditions
Prostate Cancer
Interventions
ZD4054
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Oct 14, 2026, 5:35 AM EDT
Terminated Phase 2 Interventional Results available

18F-FSPG PET/MRI or PET/CT Imaging of Cardiac Sarcoidosis or Inflammation

NCT03103490
View directory record Official record
Conditions
Cardiac Sarcoidosis, Myocardial Inflammation
Interventions
18F-FSPG
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2023 · Synced Oct 14, 2026, 5:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Feasibility Study to Determine PET/CT Imaging of Blood Flow to the Bone

NCT03557450
View directory record Official record
Conditions
Normal Subjects
Interventions
PET/CT Scan
Device
Lead sponsor
University of California, Davis
Other
Eligibility
20 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 30, 2019 · Synced Oct 14, 2026, 5:35 AM EDT
Terminated Not applicable Interventional Results available

Fluorine F 18 EF5 PET/CT Imaging in Patients With Locally Advanced or Recurrent/Metastatic Cervical Cancer

NCT00978874
View directory record Official record
Conditions
Cervical Cancer
Interventions
fludeoxyglucose F 18, fluorine F 18 EF5
Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 25, 2021 · Synced Oct 14, 2026, 5:35 AM EDT
Active, not recruiting Phase 2 Interventional

Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer

NCT05828082
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Castration-Resistant Prostate Carcinoma, Refractory Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Tuvusertib, Ultrasound Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
26
States / cities
Phoenix, Arizona • Orange, California • Aventura, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 14, 2026, 5:35 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional Results available

De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer

NCT03952585
View directory record Official record
Conditions
Basaloid Squamous Cell Carcinoma, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Squamous Cell Carcinoma, Papillary Squamous Cell Carcinoma, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Squamous Cell Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Cisplatin, Computed Tomography, Fludeoxyglucose F-18, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Other + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
493
States / cities
Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 348 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 14, 2026, 5:35 AM EDT
Recruiting Phase 1Phase 2 Interventional

Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial

NCT06357676
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Echocardiography, FDG-Positron Emission Tomography, Glofitamab, Ibrutinib, Magnetic Resonance Imaging, Obinutuzumab
Procedure · Biological · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 14, 2026, 5:35 AM EDT